115 related articles for article (PubMed ID: 18056254)
1. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.
Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H
Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254
[TBL] [Abstract][Full Text] [Related]
2. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528.
Kotsuma M; Hanzawa H; Iwata Y; Takahashi K; Tokui T
Drug Metab Dispos; 2008 Sep; 36(9):1938-43. PubMed ID: 18524873
[TBL] [Abstract][Full Text] [Related]
3. Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans.
Kotsuma M; Tokui T; Freudenthaler S; Nishimura K
Drug Metab Dispos; 2008 Aug; 36(8):1505-11. PubMed ID: 18448569
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528.
Kotsuma M; Tokui T; Freudenthaler S; Nishimura K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):545-55. PubMed ID: 19000552
[TBL] [Abstract][Full Text] [Related]
5. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
[TBL] [Abstract][Full Text] [Related]
6. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
Kitayama K; Tanimoto T; Koga T; Terasaka N; Fujioka T; Inaba T
Eur J Pharmacol; 2006 Jul; 540(1-3):121-30. PubMed ID: 16730694
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
Obach RS; Pablo J; Mash DC
Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
[TBL] [Abstract][Full Text] [Related]
8. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
9. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.
Chauret N; Dobbs B; Lackman RL; Bateman K; Nicoll-Griffith DA; Stresser DM; Ackermann JM; Turner SD; Miller VP; Crespi CL
Drug Metab Dispos; 2001 Sep; 29(9):1196-200. PubMed ID: 11502727
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
11. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
12. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
14. Tryptamine: a possible endogenous substrate for CYP2D6.
Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
[TBL] [Abstract][Full Text] [Related]
15. In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A:cholesterol acyltransferase, by liver microsomes in man.
Uchida T; Watanabe T; Van Hoogdalem EJ; Higuchi S
J Pharm Pharmacol; 1996 Oct; 48(10):1049-56. PubMed ID: 8953507
[TBL] [Abstract][Full Text] [Related]
16. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
17. Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor.
Kitayama K; Koga T; Inaba T; Fujioka T
Eur J Pharmacol; 2006 Aug; 543(1-3):123-32. PubMed ID: 16814766
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography-mass spectrometry method.
Xia ZL; Ying JY; Sheng R; Zeng S; Hu YZ; Yao TW
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):266-74. PubMed ID: 17709305
[TBL] [Abstract][Full Text] [Related]
19. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes.
Raghavan N; Zhang D; Zhu M; Zeng J; Christopher L
Drug Metab Dispos; 2005 Feb; 33(2):203-8. PubMed ID: 15507542
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
